PMID- 36172370
OWN - NLM
STAT- MEDLINE
DCOM- 20220930
LR  - 20221208
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - Ligand-based CAR-T cell: Different strategies to drive T cells in future new 
      treatments.
PG  - 932559
LID - 10.3389/fimmu.2022.932559 [doi]
LID - 932559
AB  - Chimeric antigen receptor (CAR)-based therapies are presented as innovative 
      treatments for multiple malignancies. Despite their clinical success, there is 
      scientific evidence of the limitations of these therapies mainly due to 
      immunogenicity issues, toxicities associated with the infusion of the product, 
      and relapses of the tumor. As a result, novel approaches are appearing aiming to 
      solve and/or mitigate the harmful effects of CAR-T therapies. These include 
      strategies based on the use of ligands as binding moieties or ligand-based CAR-T 
      cells. Several proposals are currently under development, with some undergoing 
      clinical trials to assess their potential benefits. In addition to these, 
      therapies such as chimeric autoantibody receptor (CAAR), B-cell receptor antigen 
      for reverse targeting (BAR), and even chimeric human leukocyte antigen (HLA) 
      antibody receptor (CHAR) have emerged, benefiting from the advantages of 
      antigenic ligands as antibody-binding motifs. This review focuses on the 
      potential role that ligands can play in current and future antitumor treatments 
      and in other types of diseases, such as autoimmune diseases or problems 
      associated with transplantation.
CI  - Copyright (c) 2022 Ramirez-Chacon, Betriu-Mendez, Bartolo-Ibars, Gonzalez, Marti 
      and Juan.
FAU - Ramirez-Chacon, Alejandro
AU  - Ramirez-Chacon A
AD  - Immunology Unit, Department of Cellular Biology, Physiology and Immunology, 
      Universitat Autonoma de Barcelona (UAB), Cerdanyola del Valles, Spain.
AD  - Laboratory of Cellular Immunology, Institute of Biotechnology and Biomedicine 
      (IBB), Cerdanyola del Valles, Spain.
FAU - Betriu-Mendez, Sergi
AU  - Betriu-Mendez S
AD  - Immunology Department, Hospital Clinic de Barcelona, Centre de Diagnostic 
      Biomedic (CDB), Barcelona, Spain.
AD  - Immunology Department, Institut d'Investigacions Biomediques August Pi i Sunyer 
      (IDIBAPS) - Fundacio Clinic per a la Recerca Biomedica (FCRB) Universitat de 
      Barcelona (UB), Barcelona, Spain.
FAU - Bartolo-Ibars, Ariadna
AU  - Bartolo-Ibars A
AD  - Immunology Department, Hospital Clinic de Barcelona, Centre de Diagnostic 
      Biomedic (CDB), Barcelona, Spain.
AD  - Immunology Department, Institut d'Investigacions Biomediques August Pi i Sunyer 
      (IDIBAPS) - Fundacio Clinic per a la Recerca Biomedica (FCRB) Universitat de 
      Barcelona (UB), Barcelona, Spain.
FAU - Gonzalez, Azucena
AU  - Gonzalez A
AD  - Immunology Department, Hospital Clinic de Barcelona, Centre de Diagnostic 
      Biomedic (CDB), Barcelona, Spain.
AD  - Immunology Department, Institut d'Investigacions Biomediques August Pi i Sunyer 
      (IDIBAPS) - Fundacio Clinic per a la Recerca Biomedica (FCRB) Universitat de 
      Barcelona (UB), Barcelona, Spain.
AD  - Immunology Department, Hospital Sant Joan de Deu, Barcelona, Spain.
FAU - Marti, Merce
AU  - Marti M
AD  - Immunology Unit, Department of Cellular Biology, Physiology and Immunology, 
      Universitat Autonoma de Barcelona (UAB), Cerdanyola del Valles, Spain.
AD  - Laboratory of Cellular Immunology, Institute of Biotechnology and Biomedicine 
      (IBB), Cerdanyola del Valles, Spain.
FAU - Juan, Manel
AU  - Juan M
AD  - Immunology Department, Hospital Clinic de Barcelona, Centre de Diagnostic 
      Biomedic (CDB), Barcelona, Spain.
AD  - Immunology Department, Institut d'Investigacions Biomediques August Pi i Sunyer 
      (IDIBAPS) - Fundacio Clinic per a la Recerca Biomedica (FCRB) Universitat de 
      Barcelona (UB), Barcelona, Spain.
AD  - Immunology Department, Hospital Sant Joan de Deu, Barcelona, Spain.
LA  - eng
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20220912
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Ligands)
RN  - 0 (Receptors, Antigen, B-Cell)
RN  - 0 (Receptors, Antigen, T-Cell)
RN  - 0 (Receptors, Chimeric Antigen)
SB  - IM
EIN - Front Immunol. 2022 Nov 21;13:1078003. PMID: 36479103
MH  - Humans
MH  - Ligands
MH  - *Neoplasms
MH  - Receptors, Antigen, B-Cell/metabolism
MH  - Receptors, Antigen, T-Cell
MH  - *Receptors, Chimeric Antigen
MH  - T-Lymphocytes
PMC - PMC9511026
OTO - NOTNLM
OT  - BAR
OT  - CAAR
OT  - T cells
OT  - antigen
OT  - chimeric antigen receptor (CAR)
OT  - ligands
OT  - receptor
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/09/30 06:00
MHDA- 2022/10/01 06:00
PMCR- 2022/01/01
CRDT- 2022/09/29 02:17
PHST- 2022/04/29 00:00 [received]
PHST- 2022/08/22 00:00 [accepted]
PHST- 2022/09/29 02:17 [entrez]
PHST- 2022/09/30 06:00 [pubmed]
PHST- 2022/10/01 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2022.932559 [doi]
PST - epublish
SO  - Front Immunol. 2022 Sep 12;13:932559. doi: 10.3389/fimmu.2022.932559. eCollection 
      2022.